Syndecan‐2 can promote clearance of T‐cell receptor/<scp>CD</scp>3 from the cell surface

Rovira-Clavé, Xavier; Angulo-Ibáñez, Maria; Noguer, Oriol; Espel, Enric; Reina, Manuel

doi:10.1111/j.1365-2567.2012.03626.x

Cited by 16 publications

(9 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…119,120 Syndecan-2 was found to be expressed in haematopoietic cells and myeloid cells, 121 and functionally reported to upregulate upon T cell activation and play a significant role in CD3 downregulation, through degradation of the T cell receptor (TCR). 122 These findings strongly suggest that enrichment of syndecan-2 expression in MSCs could play an essential role in immune modulation in injured tissue.…”

Section: Key Pointmentioning

confidence: 89%

Mesenchymal stromal cell therapy for liver diseases

Alfaifi

Eom

Newsome

et al. 2018

Journal of Hepatology

158

148

View full text Add to dashboard Cite

The therapeutic potential of mesenchymal stromal cells (MSCs) in the treatment of liver fibrosis is predominantly based on their immunosuppressive properties, and their ability to secrete various trophic factors. This potential has been investigated in clinical and preclinical studies. Although the therapeutic mechanisms of MSC transplantation are still not fully characterised, accumulating evidence has revealed that various trophic factors secreted by MSCs play key therapeutic roles in regeneration by alleviating inflammation, apoptosis, and fibrosis as well as stimulating angiogenesis and tissue regeneration in damaged liver. In this review, we summarise the safety, efficacy, potential transplantation routes and therapeutic effects of MSCs in patients with liver fibrosis. We also discuss some of the key strategies to enhance the functionality of MSCs, which include sorting and/or priming with factors such as cytokines, as well as genetic engineering.

show abstract

Section: Key Pointmentioning

confidence: 89%

Mesenchymal stromal cell therapy for liver diseases

Alfaifi

Eom

Newsome

et al. 2018

Journal of Hepatology

158

148

View full text Add to dashboard Cite

show abstract

“…For example, CD73 positivity on MSC is associated with increased capacity for self-renewal and differentiation (36). The presence of Syndecan-2 (CD-362+) on MSC has been associated with enhanced immunomodulatory properties through downregulation of CD3+ cells by degradation of the T-cell receptor (37).…”

Section: Cell Phenotype and Issues Of Batch-to-batch Variationmentioning

confidence: 99%

A Comparison of Phenotypic and Functional Properties of Mesenchymal Stromal Cells and Multipotent Adult Progenitor Cells

Khan

Newsome

2019

Front. Immunol.

View full text Add to dashboard Cite

Both Multipotent Adult Progenitor Cells and Mesenchymal Stromal Cells are bone-marrow derived, non-haematopoietic adherent cells, that are well-known for having immunomodulatory and pro-angiogenic properties, whilst being relatively non-immunogenic. However, they are phenotypically and functionally distinct cell types, which has implications for their efficacy in different settings. In this review we compare the phenotypic and functional properties of these two cell types, to help in determining which would be the superior cell type for different applications.

show abstract

“…Syndecan family consists of four distinct members that are mostly expressed on epithelial, endothelial, neural, or fibroblastic cells, but they are also detected on haemopoietic cells (17,18). Syndecan 2 and syndecan 4 are up-regulated upon CD4+ T cell activation and act as inhibitors by promoting T cell receptor (TCR) clearance or by activating tyrosine phosphatase CD148 (19,20). Syndecan 1 (CD138) is commonly used as a marker to identify plasmablasts and plasma cells (21).…”

Section: Introductionmentioning

confidence: 99%

Disease Stage-Specific Pathogenicity of CD138 (Syndecan 1)-Expressing T Cells in Systemic Lupus Erythematosus

2020

View full text Add to dashboard Cite

CD138 (syndecan 1), a member of the heparan-sulfate proteoglycan family, regulates diverse biological responses by interacting with chemokines, cytokines, growth factors, and adhesion molecules. Expression of CD138 has been detected on T cells from both healthy and sick mice mimicking systemic lupus erythematosus (SLE) disease. However, the characteristics and the role of CD138+ T cells in SLE pathogenesis remain largely unknown. We analyzed the lupus-prone MRL/Lpr mice and the control MRL/MpJ strain as well as the common laboratory strains Balb/c, and C57BL/6 for CD138-expression and found that only the MRL/Lpr strain harbored TCRβ+CD138+ cells in various organs. The frequency of TCRβ+CD138+ cells progressively expanded in MRL/Lpr mice with age and correlated with disease severity. Majority of the TCRβ+CD138+ cells were CD4 and CD8 double-negative and 20% were CD4. At least a portion of TCRβ+CD138+ cells originated from CD4+ cells because substantial number of CD4+TCRβ+CD138cells expressed CD138 after in vitro cultivation. Compared to TCRβ+CD138-cells, TCRβ+CD138+ cells exhibited central memory (Tcm) phenotype with reduced ability to proliferate and produce the cytokines IFNγ and IL-17. When co-cultured with B cells, the ability of TCRβ+CD138+ cells to promote plasma cell formation and autoreactive antibody production was dependent on the presence of autoantigen, CD4 co-receptor expression and cell-to-cell contact. Surprisingly, adoptively transferred TCRβ+CD138+ T cells slowed down disease progression in young recipient MRL/Lpr mice but had the opposite effect when DNA was co-administered with TCRβ+CD138+ T cells or when TCRβ+CD138+ cells were transferred to older MRL/Lpr mice with established disease. Thus, CD138-expressing T cells with Tcm phenotype enhance disease progression in SLE by rapidly activating autoreactive B cells when self-antigens are exposed to the immune system.

show abstract

Syndecan‐2 can promote clearance of T‐cell receptor/CD3 from the cell surface

Cited by 16 publications

References 49 publications

Mesenchymal stromal cell therapy for liver diseases

Mesenchymal stromal cell therapy for liver diseases

A Comparison of Phenotypic and Functional Properties of Mesenchymal Stromal Cells and Multipotent Adult Progenitor Cells

Disease Stage-Specific Pathogenicity of CD138 (Syndecan 1)-Expressing T Cells in Systemic Lupus Erythematosus

Contact Info

Product

Resources

About